<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput xmlns:ns2="local" id="79955"><DrugName>nevanimibe hydrochloride (oral, adrenal cancer/congenital adrenal hyperplasia/adrenal cortical carcinoma/cushings syndrome) Millendo Therapeutics</DrugName><DrugNamesKey><Name id="43116227">nevanimibe</Name><Name id="43120365">nevanimibe hydrochloride</Name></DrugNamesKey><DrugSynonyms><Name><Value>PD-132301-2</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>adrenal cancer therapy, Atterocor</Value></Name><Name><Value>ACAT inhibitor (adrenal cancer), Atterocor</Value></Name><Name><Value>ACAT inhibitor (oral, adrenal cancer), Atterocor</Value></Name><Name><Value>ATR-101</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>nevanimibe</Value><Types><Type>USAN</Type><Type>PINN</Type></Types></Name><Name><Value>nevanimibe hydrochloride</Value><Types><Type>USAN</Type></Types></Name><Name><Value>nevanimibe hydrochloride (oral, adrenal cancer) Millendo Therapeutics</Value></Name><Name><Value>133825-81-7</Value><Types><Type>CAS RN</Type></Types></Name><Name><Value>133825-80-6</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="1072027">Millendo Therapeutics Inc</CompanyOriginator><CompaniesPrimary><Company id="1072027">Millendo Therapeutics Inc</Company></CompaniesPrimary><CrossReferences><SourceEntity id="1072027" type="Company"><TargetEntity id="5037636416" type="organizationId">Millendo Therapeutics US Inc</TargetEntity></SourceEntity><SourceEntity id="1648" type="ciIndication"><TargetEntity id="10001388" type="MEDDRA"></TargetEntity><TargetEntity id="D018268" type="MeSH"></TargetEntity><TargetEntity id="-1334960598" type="omicsDisease"></TargetEntity><TargetEntity id="1336" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1654" type="ciIndication"><TargetEntity id="10061630" type="MEDDRA"></TargetEntity><TargetEntity id="D000312" type="MeSH"></TargetEntity></SourceEntity><SourceEntity id="2049" type="ciIndication"><TargetEntity id="C74.9" type="ICD10"></TargetEntity><TargetEntity id="C74" type="ICD10"></TargetEntity><TargetEntity id="194.0" type="ICD9"></TargetEntity><TargetEntity id="10001376" type="MEDDRA"></TargetEntity><TargetEntity id="D000310" type="MeSH"></TargetEntity><TargetEntity id="-940608138" type="omicsDisease"></TargetEntity><TargetEntity id="2905" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3484" type="ciIndication"><TargetEntity id="E24" type="ICD10"></TargetEntity><TargetEntity id="10011652" type="MEDDRA"></TargetEntity><TargetEntity id="D003480" type="MeSH"></TargetEntity><TargetEntity id="553" type="ORPHANET"></TargetEntity><TargetEntity id="-1380874501" type="omicsDisease"></TargetEntity><TargetEntity id="505" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="14205" type="Action"><TargetEntity id="2238" type="Mechanism">ACAT 1 Inhibitors</TargetEntity></SourceEntity><SourceEntity id="1545" type="Action"><TargetEntity id="4426" type="Mechanism">Immune Checkpoint Inhibitors</TargetEntity><TargetEntity id="4644" type="Mechanism">Anti-PD-L1/ VISTA Immune Checkpoint</TargetEntity><TargetEntity id="1937" type="Mechanism">Anti-Tumor Associated Glycoprotein 72 (TAG-72)</TargetEntity></SourceEntity><SourceEntity id="1589" type="Action"><TargetEntity id="1062" type="Mechanism">Apoptosis Inducers</TargetEntity></SourceEntity><SourceEntity id="PTGT-03616" type="ciTarget"><TargetEntity id="62339649366463" type="siTarget">Sterol O-acyltransferase 1</TargetEntity><TargetEntity id="-969018995" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="C2">Phase 2 Clinical</PhaseHighest><RegulatoryDesignations><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication id="1648">Adrenal cortical carcinoma</Indication><Indication id="1654">Congenital adrenal hyperplasia</Indication><Indication id="3484">Cushings syndrome</Indication></IndicationsPrimary><IndicationsSecondary><Indication id="2049">Adrenal gland tumor</Indication></IndicationsSecondary><ActionsPrimary><Action id="14205">ACAT-1 inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="1545">Anticancer</Action><Action id="7293">Synergist</Action><Action id="1589">Apoptosis stimulator</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology><Technology id="585">Oral formulation</Technology></Technologies><LastModificationDate>2019-06-29T05:32:59.000Z</LastModificationDate><ChangeDateLast>2019-05-21T00:00:00.000Z</ChangeDateLast><AddedDate>2012-08-06T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="1072027" linkType="Company"&gt;Millendo Therapeutics&lt;/ulink&gt; (previously Atterocor) is developing nevanimibe (ATR-101,   &lt;ulink linkID="3834" linkType="Drug"&gt;PD-132301-2&lt;/ulink&gt;), an ACAT1 inhibitor,  for the potential oral treatment of congenital adrenal hyperplasia (CAH), Cushing's syndrome and adrenal cancers including adrenocortical cancer   [&lt;ulink linkID="1313093" linkType="Reference"&gt;1313093&lt;/ulink&gt;], [&lt;ulink linkID="1411042" linkType="Reference"&gt;1411042&lt;/ulink&gt;], [&lt;ulink linkID="1451803" linkType="Reference"&gt;1451803&lt;/ulink&gt;], [&lt;ulink linkID="1487860" linkType="Reference"&gt;1487860&lt;/ulink&gt;], [&lt;ulink linkID="1607757" linkType="Reference"&gt;1607757&lt;/ulink&gt;], [&lt;ulink linkID="1724864" linkType="Reference"&gt;1724864&lt;/ulink&gt;], [&lt;ulink linkID="1725014" linkType="Reference"&gt;1725014&lt;/ulink&gt;], [&lt;ulink linkID="1626165" linkType="Reference"&gt;1626165&lt;/ulink&gt;], [&lt;ulink linkID="1993105" linkType="Reference"&gt;1993105&lt;/ulink&gt;]. In June 2016, a phase II study was initiated for congenital adrenal hyperplasia [&lt;ulink linkID="1770713" linkType="Reference"&gt;1770713&lt;/ulink&gt;], [&lt;ulink linkID="1892760" linkType="Reference"&gt;1892760&lt;/ulink&gt;]; in November 2017, top-line data were reported [&lt;ulink linkID="1979840" linkType="Reference"&gt;1979840&lt;/ulink&gt;]. In August 2018, another  phase IIb trial in CAH was initiated [&lt;ulink linkID="2072546" linkType="Reference"&gt;2072546&lt;/ulink&gt;], [&lt;ulink linkID="2072253" linkType="Reference"&gt;2072253&lt;/ulink&gt;]; in May 2019, preliminary data were reported based on which trial protocol amendment was submitted [&lt;ulink linkID="2152131" linkType="Reference"&gt;2152131&lt;/ulink&gt;].  In February  2017, a phase II study  was initiated for Cushing's syndrome  [&lt;ulink linkID="1911220" linkType="Reference"&gt;1911220&lt;/ulink&gt;]. In July 2013, a phase I trial was initiated in the US for adrenocortical cancer; in October 2017, trial was completed  [&lt;ulink linkID="1452816" linkType="Reference"&gt;1452816&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;In March 2012, the FDA granted Orphan status to ATR-101 for the treatment of adrenocortical carcinoma [&lt;ulink linkID="1487860" linkType="Reference"&gt;1487860&lt;/ulink&gt;], [&lt;ulink linkID="1626164" linkType="Reference"&gt;1626164&lt;/ulink&gt;]. In January 2015, the FDA granted the drug Orphan designation for the treatment of Cushing's syndrome [&lt;ulink linkID="1626165" linkType="Reference"&gt;1626165&lt;/ulink&gt;]. In August 2017, the drug was awarded Orphan designation for treatment of congenital adrenal hyperplasia [&lt;ulink linkID="1955403" linkType="Reference"&gt;1955403&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;In April 2013, the EMA's COMP recommended granting the drug Orphan status for the treatment of adrenocortical carcinoma [&lt;ulink linkID="1411042" linkType="Reference"&gt;1411042&lt;/ulink&gt;]; in June 2013, Orphan status was granted [&lt;ulink linkID="1442730" linkType="Reference"&gt;1442730&lt;/ulink&gt;]. In December 2017, the COMP recommended granting Orphan designation for treatment of congenital adrenal hyperplasia [&lt;ulink linkID="1991384" linkType="Reference"&gt;1991384&lt;/ulink&gt;]; in January 2018, the Orphan designation was granted [&lt;ulink linkID="2003023" linkType="Reference"&gt;2003023&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Cushings syndrome&lt;/subtitle&gt;In January 2017, the company was planning to initiate a phase II trial in patients with Cushing's syndrome [&lt;ulink linkID="1892738" linkType="Reference"&gt;1892738&lt;/ulink&gt;]. In February  2017, a multicenter, randomized, double-blind, placebo-controlled, dose-escalation, phase II study  (&lt;ulink linkID="288339" linkType="Protocol"&gt;NCT03053271&lt;/ulink&gt;; ATR-101-301) to assess the efficacy and safety of ATR-101 in patients  (expected n = 16) with endogenous Cushing's syndrome, was initiated in the US. The study was to complete in November 2018 [&lt;ulink linkID="1911220" linkType="Reference"&gt;1911220&lt;/ulink&gt;]. In March 2017, the two-part  study consists of a 6-week open-label intra-subject dose-escalation period and a 4-week double-blind randomized withdrawal period. At that time, the trial was to be conducted in the UK [&lt;ulink linkID="1912219" linkType="Reference"&gt;1912219&lt;/ulink&gt;]. In December 2018, the trial was ongoing in the UK [&lt;ulink linkID="2102528" linkType="Reference"&gt;2102528&lt;/ulink&gt;]. In February 2019, the trial was expected to complete in November 2020 [&lt;ulink linkID="1911220" linkType="Reference"&gt;1911220&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Congenital adrenal hyperplasia&lt;/subtitle&gt;In August 2018, a phase IIb trial was planned to be initiated in the third quarter of 2018 [&lt;ulink linkID="2062012" linkType="Reference"&gt;2062012&lt;/ulink&gt;]. Later that month, the open-label, multicenter, intra-subject, dose-titration, single group assignment, interventional, phase IIb trial (&lt;ulink linkID="353400" linkType="Protocol"&gt;NCT03669549&lt;/ulink&gt;; ATR-101-202) to evaluate longer durations of treatment and higher doses of nevanimibe in patients with classic CAH (expected n = 24) was initiated in Europe and Israel. The primary endpoint was the assessment of the percentage of patients that achieve 17-OHP levels &amp;lt;/=  two times the upper limit of normal (ULN). At that time, the trial  was expected to complete in March 2020 [&lt;ulink linkID="2072546" linkType="Reference"&gt;2072546&lt;/ulink&gt;], [&lt;ulink linkID="2072253" linkType="Reference"&gt;2072253&lt;/ulink&gt;]. In December 2018, data were expected in the first half of 2020 [&lt;ulink linkID="2102528" linkType="Reference"&gt;2102528&lt;/ulink&gt;]. In May 2019, preliminary data were reported. Data demonstrated lower tolerability than expected based on prior clinical experience. The enrollment was paused while a protocol amendment was submitted to add a lower starting dose. The patients currently enrolled in the study would continue as per protocol and might dose escalate as planned [&lt;ulink linkID="2152131" linkType="Reference"&gt;2152131&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2016, a phase  II multicenter, single-blind, multiple dose, efficacy and safety  study began in patients with classic CAH resulting from 21-hydroxylase deficiency [&lt;ulink linkID="1770713" linkType="Reference"&gt;1770713&lt;/ulink&gt;]. Later that month, the phase II trial (&lt;ulink linkID="263589" linkType="Protocol"&gt;NCT02804178&lt;/ulink&gt;; ATR-101-201) was ongoing in the US in patients (expected n = 17) with congenital adrenal hyperplasia. At that time, the trial was expected to complete in September 2017  [&lt;ulink linkID="1892760" linkType="Reference"&gt;1892760&lt;/ulink&gt;]. In August 2017, trial was completed [&lt;ulink linkID="1892760" linkType="Reference"&gt;1892760&lt;/ulink&gt;]. In November 2017, topline data were reported. Data demonstrated that seven out of 10 patients exhibited a clear biological effect as measured by reductions  in 17-hydroxyprogesterone (17-OHP). The trial was stopped early and only 10 patients were recruited due to the demonstration of biological effect. Overall, the drug was well-tolerated [&lt;ulink linkID="1979840" linkType="Reference"&gt;1979840&lt;/ulink&gt;]. In March 2018, similar data were presented at the 100th Endocrine Society Annual Meeting in Chicago, IL [&lt;ulink linkID="2015007" linkType="Reference"&gt;2015007&lt;/ulink&gt;], [&lt;ulink linkID="2015450" linkType="Reference"&gt;2015450&lt;/ulink&gt;]. By August 2018, data from the trial were reported, data demonstrated positive proof-of-concept and a favorable safety profile in CAH [&lt;ulink linkID="2062012" linkType="Reference"&gt;2062012&lt;/ulink&gt;]. In March 2019, similar data were presented at the 2019 Endocrine Society Annual Meeting in New Orleans, LA. A decrease in 17-OHP of at least 50% during at least one nevanimibe administration period was seen in 70% of patients: no patients experienced a mean decrease during placebo washout periods. Adverse event rates were similar between treatment and placebo [&lt;ulink linkID="2131162" linkType="Reference"&gt;2131162&lt;/ulink&gt;], [&lt;ulink linkID="2133004" linkType="Reference"&gt;2133004&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Adrenal cortical carcinoma&lt;/subtitle&gt;In July 2013, the company planned to initiate clinical development in 2013 [&lt;ulink linkID="1451803" linkType="Reference"&gt;1451803&lt;/ulink&gt;]; later that month, an open-label, single-group, phase I study (&lt;ulink linkID="145712" linkType="Protocol"&gt;NCT01898715&lt;/ulink&gt;; ATR-101-001) to assess the safety, tolerability and efficacy of ATR-101 was initiated in patients (expected n = 21) with advanced adrenocortical cancer in the US. At that time, the trial was expected to complete in August 2014 [&lt;ulink linkID="1452816" linkType="Reference"&gt;1452816&lt;/ulink&gt;], [&lt;ulink linkID="1487860" linkType="Reference"&gt;1487860&lt;/ulink&gt;]. In June 2014, clinical data were presented at the 16th ICE/96th ENDO Joint conference in Chicago, IL. Dose doubling of the drug was ongoing and no DLTs had been observed. At that time, investigation of cohort 6 (51.2 mg/kg/day po) was continuing and subjects were being actively recruited for dose-escalation and -expansion cohorts, with expansion to further sites in the US and EU undergoing approval [&lt;ulink linkID="1570619" linkType="Reference"&gt;1570619&lt;/ulink&gt;], [&lt;ulink linkID="1571963" linkType="Reference"&gt;1571963&lt;/ulink&gt;]. In October 2014, the company planned to complete the trial and the data were expected in 2015 [&lt;ulink linkID="1607757" linkType="Reference"&gt;1607757&lt;/ulink&gt;]. In December 2014, the company expanded the trial with three additional clinical trial centers in the US and Germany that included the National Cancer Institute in Bethesda, MD, H. Lee Moffitt Cancer Center in Tampa, FL and the Comprehensive Cancer Center Mainfranken, University Hospital of Würzburg in Germany [&lt;ulink linkID="1620177" linkType="Reference"&gt;1620177&lt;/ulink&gt;]. In March 2015, clinical data were presented at the 97th Annual Meeting and Exposition of the Endocrine Society in San Diego, CA.												The dose escalation of ATR-101 was continued and tablet formulation was introduced for improved pharmacokinetics. At the time of presentation, actively recruiting subjects for dose escalation and expansion cohorts [&lt;ulink linkID="1638290" linkType="Reference"&gt;1638290&lt;/ulink&gt;]. In October 2017, trial was completed [&lt;ulink linkID="1452816" linkType="Reference"&gt;1452816&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In April 2017, in vitro data were presented at the 99th Endocrine Society Annual Meeting in Orlando, FL. In ACC H295R cells, the combination treatment of ATR-101 and thapsigargin caused concurrent inhibition of ACAT1 and activation of ER stress, and induced cell death induced cell death; and the combination treatment of ATR-101 and bortezomib caused combined inhibition of ACAT1 and unfolded protein response, and induced cell death. At sub-toxic concentrations, ACC cell death was synergistically increased after ATR-101 treatment in combination with thapsigargin or bortezomib [&lt;ulink linkID="1913163" linkType="Reference"&gt;1913163&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2016, data demonstrated that ATR-101 had efficacy in loweing ACTH-stimulated cortisol levels in both pituitary- and adrenal-dependent disease states, in canines with naturally-occurring Cushing's syndrome. At that time,  data were to be presented at the Society for Endocrinology (SfE) British Endocrine Societies (BES) 2016 conference in Brighton, UK [&lt;ulink linkID="1869275" linkType="Reference"&gt;1869275&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2016, preclinical data were presented at the 98th Endocrine Society Annual Meeting in Boston, MA. Pharmacokinetic parameter values were similar in male and female dogs; both Cmax and AUC0 to 24 increased with increasing dose. Decreases in ACTH-stimulated cortisol release were dose-dependent and persisted for the duration of treatment. ATR-101 was well tolerated [&lt;ulink linkID="1745283" linkType="Reference"&gt;1745283&lt;/ulink&gt;]. In November 2016, in vivo data were to be presented at the SfE BES 2016 conference in Brighton, UK [&lt;ulink linkID="1869275" linkType="Reference"&gt;1869275&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2016, data were published. Data demonstrated that   selective inhibition of ACAT1 by ATR-101 increased free cholesterol levels in the H295R human ACC cell line, resulting in dysregulation of endoplasmic reticulum  calcium (ER) stores, ER stress, activation of the unfolded protein response, and apoptosis.  In vivo treatment of dogs with ATR-101 decreased adrenocortical steroid production and induced cellular apoptosis that was restricted to the adrenal cortex. At that time, data were expected to be presented at The Endocrine Society's 98th Annual Meeting &amp;amp; Expo, in April 2016, in Boston, MA [&lt;ulink linkID="1744987" linkType="Reference"&gt;1744987&lt;/ulink&gt;], [&lt;ulink linkID="1744935" linkType="Reference"&gt;1744935&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2015, preclinical data were presented at the 97th Annual Meeting and Exposition of the Endocrine Society in San Diego, CA. ATR-101 induced cell death by inhibiting ACAT-1 which resulted in toxic levels of free cholesterol in ACC cells and sensitized H295R adrenocortical carcinoma cells to ATR-101-induced death [&lt;ulink linkID="1637990" linkType="Reference"&gt;1637990&lt;/ulink&gt;]. Further preclinical data were also presented at the same conference. In dogs with Cushing's syndrome, treatment with po ATR-101  significantly decreased post-adrenocorticotropic hormone (ACTH) stimulated cortisol concentrations from 864.9 to 458.3, 392.2 and 418.3 nMol/l at weeks 1, 2 and 4, respectively. By study completion, the mean ALT and alkaline phosphatase activities were increased [&lt;ulink linkID="1638289" linkType="Reference"&gt;1638289&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2014, preclinical data were presented at the 16th ICE/96th ENDO Joint conference in Chicago, IL. n H295R adrenocortical carcinoma cells, ATR-101 (3 or 30 microM) decreased viability and caused apoptosis of cells by inhibiting esterification of free cholesterol. Expression of genes involved in steroidogenesis was dysregulated by ATR-101  [&lt;ulink linkID="1570617" linkType="Reference"&gt;1570617&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2014, preclinical data were presented at the 16th ICE/96th ENDO Joint conference in Chicago, IL. In dogs, ATR-101 treatment resulted in a dose-dependent decrease in cortisol secretion, a simultaneous increase in ACTH and a decrease in the amount of steroid precursors assessed. At the highest doses tested, there was no effect on the clinical appearance of dogs or significant effect on routine laboratory parameters [&lt;ulink linkID="1570619" linkType="Reference"&gt;1570619&lt;/ulink&gt;], [&lt;ulink linkID="1571963" linkType="Reference"&gt;1571963&lt;/ulink&gt;]. Further data were presented at the same conference.  Dose-related plasma exposure was observed with ATR-101 and the levels were highest in adrenals compared to other tissues. There was a decreased in the cholesterol ester levels. Rapid, dose-dependent decreases in adreno cortico-stimualating hormone-stimulated cortisol levels were observed. ATR-101 induced significant apoptosis in the zona reticularis and zona fasciculata [&lt;ulink linkID="1571304" linkType="Reference"&gt;1571304&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By July 2013, results from preclinical studies had shown selective effects of ATR-101 on cells derived from the adrenal cortex [&lt;ulink linkID="1451803" linkType="Reference"&gt;1451803&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1072027">Millendo Therapeutics Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1654">Congenital adrenal hyperplasia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-08-01T00:00:00.000Z</StatusDate><Source id="2072546" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1072027">Millendo Therapeutics Inc</Company><Country id="IL">Israel</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1654">Congenital adrenal hyperplasia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-08-01T00:00:00.000Z</StatusDate><Source id="2072546" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1072027">Millendo Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3484">Cushings syndrome</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-02-16T00:00:00.000Z</StatusDate><Source id="1911220" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1072027">Millendo Therapeutics Inc</Company><Country id="GB">UK</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3484">Cushings syndrome</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-12-07T00:00:00.000Z</StatusDate><Source id="2102528" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1072027">Millendo Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1654">Congenital adrenal hyperplasia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-06-08T00:00:00.000Z</StatusDate><Source id="1770713" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1072027">Millendo Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1648">Adrenal cortical carcinoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-07-10T00:00:00.000Z</StatusDate><Source id="1452816" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1072027">Millendo Therapeutics Inc</Company><Country id="DE">Germany</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1648">Adrenal cortical carcinoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-12-11T00:00:00.000Z</StatusDate><Source id="1620177" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1072027">Millendo Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="2049">Adrenal gland tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-08-03T00:00:00.000Z</StatusDate><Source id="1313093" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1072027">Millendo Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1648">Adrenal cortical carcinoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-03-09T00:00:00.000Z</StatusDate></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1072027">Millendo Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1654">Congenital adrenal hyperplasia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-01-06T00:00:00.000Z</StatusDate><Source id="1725014" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1072027">Millendo Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3484">Cushings syndrome</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-01-07T00:00:00.000Z</StatusDate></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1072027">Millendo Therapeutics Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1654">Congenital adrenal hyperplasia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-12-05T00:00:00.000Z</StatusDate><Source id="1991384" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1072027">Millendo Therapeutics Inc</Company><Country id="GB">UK</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3484">Cushings syndrome</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-03-28T00:00:00.000Z</StatusDate><Source id="1912219" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1072027">Millendo Therapeutics Inc</Company><Country id="FR">France</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1654">Congenital adrenal hyperplasia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-08-01T00:00:00.000Z</StatusDate><Source id="2072546" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1072027">Millendo Therapeutics Inc</Company><Country id="ES">Spain</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1654">Congenital adrenal hyperplasia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-08-01T00:00:00.000Z</StatusDate><Source id="2072546" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1072027">Millendo Therapeutics Inc</Company><Country id="CZ">Czech Republic</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1654">Congenital adrenal hyperplasia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-08-01T00:00:00.000Z</StatusDate><Source id="2072546" type="TRIALREG"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1072027">Millendo Therapeutics Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="1654">Congenital adrenal hyperplasia</Indication><AwardedIndication>Treatment of congenital adrenal hyperplasia</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-01-17T00:00:00.000Z</MileStoneDate><Source id="2003023" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1072027">Millendo Therapeutics Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="1654">Congenital adrenal hyperplasia</Indication><AwardedIndication>Treatment of congenital adrenal hyperplasia</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-12-07T00:00:00.000Z</MileStoneDate><Source id="1991384" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1072027">Millendo Therapeutics Inc</OwnerCompany><Country id="US">US</Country><Indication id="1654">Congenital adrenal hyperplasia</Indication><AwardedIndication>Treatment of congenital adrenal hyperplasia</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-08-17T00:00:00.000Z</MileStoneDate><Source id="1955403" type="CORPORATE"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1072027">Millendo Therapeutics Inc</OwnerCompany><Country id="US">US</Country><Indication id="3484">Cushings syndrome</Indication><AwardedIndication>For the treatment of Cushing's Syndrome</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-01-07T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1072027">Millendo Therapeutics Inc</OwnerCompany><Country id="US">US</Country><Indication id="1648">Adrenal cortical carcinoma</Indication><AwardedIndication>Treatment of adrenocortical carcinoma</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-06-07T00:00:00.000Z</MileStoneDate><Source id="1442730" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1072027">Millendo Therapeutics Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="1648">Adrenal cortical carcinoma</Indication><AwardedIndication>Treatment of adrenocortical carcinoma</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-06-07T00:00:00.000Z</MileStoneDate><Source id="1442730" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1072027">Millendo Therapeutics Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="1648">Adrenal cortical carcinoma</Indication><AwardedIndication>Treatment of adrenocortical carcinoma</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-04-17T00:00:00.000Z</MileStoneDate><Source id="1411042" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1072027">Millendo Therapeutics Inc</OwnerCompany><Country id="US">US</Country><Indication id="1648">Adrenal cortical carcinoma</Indication><AwardedIndication>Treatment of adrenocortical carcinoma</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-04-17T00:00:00.000Z</MileStoneDate><Source id="1411042" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1072027">Millendo Therapeutics Inc</OwnerCompany><Country id="US">US</Country><Indication id="1648">Adrenal cortical carcinoma</Indication><AwardedIndication>Treatment of adrenocortical carcinoma</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-03-09T00:00:00.000Z</MileStoneDate><Source id="1487860" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1072027">Millendo Therapeutics Inc</OwnerCompany><Country id="US">US</Country><Indication id="1648">Adrenal cortical carcinoma</Indication><AwardedIndication>Treatment of adrenocortical carcinoma</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-03-09T00:00:00.000Z</MileStoneDate><Source id="1487860" type="PR"></Source></Row></RegulatoryDesignationStatus><Targets><Target id="PTGT-03616"><Name>ACAT-1</Name><SwissprotNumbers><Swissprot>O70536</Swissprot><Swissprot>O77760</Swissprot><Swissprot>O77761</Swissprot><Swissprot>P35610</Swissprot><Swissprot>Q60457</Swissprot><Swissprot>Q61263</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1072027">Millendo Therapeutics Inc</Company><CountAsPrincipalActive>2</CountAsPrincipalActive><CountAsPrincipalInactive>1</CountAsPrincipalInactive><CountAsPartnerActive>2</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>3</CountTotal></Company><Company><Company id="20623">University of Michigan</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="21864">University of Texas System</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="20">Company - M&amp;A (in whole or part)</Type><CountActive>0</CountActive><CountInactive>1</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="7">Drug - Development Services</Type><CountActive>2</CountActive><CountInactive>0</CountInactive><CountTotal>2</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>CC(C)c1cccc(c1NC(=O)NCC2(CCCC2)c3ccc(cc3)N(C)C)C(C)C.Cl</Smiles><Smiles>CC(C)c1cccc(c1NC(=O)NCC2(CCCC2)c3ccc(cc3)N(C)C)C(C)C</Smiles></StructureSmiles><Deals><Deal id="147003" title="UM Cancer Center to conduct a clinical study of Atterocor's ATR-101 for adrenocortical carcinoma"></Deal><Deal id="147004" title="MD Anderson Cancer Center to conduct a clinical study of Atterocor's ATR-101 for adrenocortical carcinoma"></Deal><Deal id="249128" title="OvaScience reverse merges with Millendo Therapeutics to form a rare endocrine disease company"></Deal></Deals><PatentFamilies><PatentFamily id="2594555" number="WO-2013142214" title="Compounds and methods for treating aberrant adrenocartical cell disorders"></PatentFamily><PatentFamily id="3511439" number="WO-2017011302" title="Enhanced bioavailability of N-(2,6-bis(1-methylethyl) phenyl)-N'-((1-(4-(dimethylamino)-phenyl)cyclopentyl) methyl)urea hydrochloride"></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Millendo Therapeutics Inc" id="1072027"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Michigan" id="20623"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput>